Insider trades
Stock that executives, directors and 10% owners bought and sold on the open market, from the Form 4s they file with the SEC within two business days. Grants, option exercises and shares sold to cover taxes are left out.
- $79.2M bought by 61 insiders at 47 companies
- $239M sold by 49 insiders outside a trading plan
- $2.5B sold by 203 insiders under 10b5-1 plans
- 10 companies where two or more insiders bought (30 days)
Biggest buys
Past week, each insider's filings added up.
-
CRBGCorebridge FinancialLife Insurance Co Nippon10% owner$49.2M
-
DOLEDole PLCPale Fire Capital SE10% owner, +4 joint filers$8.6M
-
APLDApplied DigitalJason Gechen ZhangPresident$5.7M
-
RENTRent the RunwaySTORY3 Capital Partners, LLCDirector, +3 joint filers$2.2M
-
RENTRent the RunwayCHS US Investments LLC10% owner, +4 joint filers$1.6M
-
FBKFB FinancialOrrin H Ingram IIDirector$1.5M
-
TENXTenax TherapeuticsADAR1 Capital Management, LLC10% owner, +1 joint filer$1.5M
-
APLDApplied DigitalWes CumminsCEO$1M
-
RAPPRapport TherapeuticsSteven M PaulDirector$974K
-
SNESSenesTechGlenbrook Capital Management10% owner$781K
Biggest sales
Past week, each insider's filings added up. Planned sales are marked.
-
IHTInnSuites Hospitality TrustJames F WirthCEO$2B
-
SNOWSnowflakeFrank SlootmanDirector$94.9M
-
TALOTalos EnergyEmpresarial De Capitales S.a. De C.v. Control10% owner$85.9M
-
TRVTravelersAlan D SchnitzerCEO$35.3M
-
PATHUiPathDaniel DinesCEO$33.1M
-
UTHRUnited TherapeuticsMartine A RothblattCEO$26.4M
-
MUMicron TechnologyScott J DeboerPres. & Chief Tech & Prod Offr$25.7M
-
ALMRAlamar BiosciencesQiming Corporate GP VI, Ltd.10% owner, +6 joint filers$21M
-
SNOWSnowflakeBenoit DagevilleDirector$16.1M
-
LINDLindblad ExpeditionsSven-Olof LindbladDirector$14.3M
Cluster buying
Companies where two or more insiders bought on the open market in the last 30 days, most buyers first
-
Che-Chia Wei CEO, Yuh-Jier Mii COO, Yung-Pei Chin COO, Yung-Chin Hou COO, +15 more
-
Reuben S Leibowitz Director, Larry C Glasscock Director, Daniel C. Smith Director, Gary M Rodkin Director, +7 more
-
R Jeffrey Bailly Director, Daniel L Florness Director, Srilata Zaheer Director, Charles T Lauber Director, +5 more
-
Steven M Paul Director, John Maraganore Director, Troy A. Ignelzi CFO, Wendy B. Young Director, +2 more
-
Thomas Jon Hammond Director, Sandip I Patel CFO, John Martin Schaible Chair, David Craig Ridenhour President, +1 more
-
John B Williamson III Director, Robert B Johnston Director, Paul W Nester CEO, Lawrence T. Oliver Senior VP and Secretary, +1 more
-
Michael Jordan Osborn CEO, John Walter Hazlett CFO, Gregory William Voorhies Director, James W Bernau President, +1 more
-
Matthew G De Soto Director, Albert J. Evans Director, Joel L. Frank Director, Theodore W Mowery Director, +1 more
-
Smriti Laxman Popenoe CEO, Byron L Boston CEO, Terrence John Connelly Jr. Chief Investment Officer, Michael Andrew Sartori CFO
-
Lewis H Titterton Jr. Director, Amit Kumar CEO, Michael Catelani CFO, Arnold M Baskies Director
ARTV insider trades
Every open-market buy and sale in ARTV, one row per filing, newest first
-
Fred Aslan CEOARTVArtiva BiotherapeuticsPlanned sale$169K 23,463 shares at $7.20 1.5% of stakeTraded Oct 6 Filed Oct 7
-
Fred Aslan CEOARTVArtiva BiotherapeuticsPlanned sale$256K 23,429 shares at $10.92 1.6% of stakeTraded Sep 8 Filed Sep 9
-
Subhashis Banerjee Chief Medical OfficerARTVArtiva BiotherapeuticsPlanned sale$99K 8,222 shares at $12.01 5.5% of stakeTraded Aug 27 Filed Aug 31
-
Subhashis Banerjee Chief Medical OfficerARTVArtiva BiotherapeuticsPlanned sale$5,148 429 shares at $12.00 0.3% of stakeTraded Aug 18 Filed Aug 19
-
Ra Capital Management, L.P. Director, +5 joint filersARTVArtiva BiotherapeuticsBuy$456K 45,768 shares at $9.96 +0.3% to stakeTraded Jul 29–31 Filed Jul 31
-
Ra Capital Management, L.P. Director, +5 joint filersARTVArtiva BiotherapeuticsBuy$413K 41,319 shares at $9.99 +0.2% to stakeTraded Jul 24 Filed Jul 28
-
Ra Capital Management, L.P. Director, +5 joint filersARTVArtiva BiotherapeuticsBuy$2.6M 264,586 shares at $9.76 +1.6% to stakeTraded Jul 21–23 Filed Jul 23
-
Ra Capital Management, L.P. Director, +5 joint filersARTVArtiva BiotherapeuticsBuy$58K 6,522 shares at $8.94 +<0.1% to stakeTraded Jul 13 Filed Jul 23
-
Ra Capital Management, L.P. Director, +5 joint filersARTVArtiva BiotherapeuticsBuy$1.4M 160,354 shares at $8.93 +1% to stakeTraded Jul 16–17 Filed Jul 20
-
Ra Capital Management, L.P. Director, +5 joint filersARTVArtiva BiotherapeuticsBuy$135K 15,102 shares at $8.97 +0.1% to stakeTraded Jul 10 Filed Jul 14
-
Ra Capital Management, L.P. Director, +5 joint filersARTVArtiva BiotherapeuticsBuy$292K 32,876 shares at $8.89 +0.2% to stakeTraded Jun 25–26 Filed Jun 29
-
Ra Capital Management, L.P. Director, +5 joint filersARTVArtiva BiotherapeuticsBuy$4.6M 531,326 shares at $8.66 +3.3% to stakeTraded Jun 12–16 Filed Jun 16
-
Ra Capital Management, L.P. Director, +5 joint filersARTVArtiva BiotherapeuticsBuy$7.7M 1,027,722 shares at $7.44 +6.8% to stakeTraded Jun 9–11 Filed Jun 11
-
GC Corp. 10% owner, +1 joint filerARTVArtiva BiotherapeuticsBuy$16.5M 1,432,291 shares at $11.52Traded May 11 Filed May 28
-
Ra Capital Management, L.P. Director, +5 joint filersARTVArtiva BiotherapeuticsBuy$75M 6,510,416 shares at $11.52 +75% to stakeTraded May 11 Filed May 13
-
Fred Aslan CEOARTVArtiva BiotherapeuticsPlanned sale$19K 3,187 shares at $6.00 0.3% of stakeTraded Dec 15, 2025 Filed Dec 15, 2025
-
Fred Aslan CEOARTVArtiva BiotherapeuticsPlanned sale$22K 6,375 shares at $3.38 1.8% of stakeTraded Nov 17, 2025 Filed Nov 17, 2025
-
Fred Aslan CEOARTVArtiva BiotherapeuticsPlanned sale$153K 25,500 shares at $6.00 6.7% of stakeTraded Oct 17, 2025 Filed Oct 17, 2025
About this data
- Officers, directors and anyone owning more than 10% of a company must report a trade in its stock on a Form 4 within two business days. We read each filing from SEC EDGAR and link to it on every row.
- Only open-market purchases and sales of common stock count here. Stock grants, option exercises, gifts and shares withheld or sold to pay taxes on vesting awards are not decisions to buy or sell, so they are left out.
- A planned sale was made under a Rule 10b5-1 trading plan, which the insider set up months in advance. Many executives sell this way on a schedule, so a planned sale says less than one made on the day.
- Values are shares times the price reported. When a filing amends an earlier one, the amended trades replace the originals. Related owners (a fund and its manager) who report the same trade separately are shown once.
- We cover the 4,839 US companies on our earnings calendar, with a year of history. The superinvestor notes count the featured 13F managers who added or cut the stock in their latest quarter.